LAURA Trial Defines Role of EGFR-directed Therapy in Unresectable Stage III NSCLC

ADRIATIC Demonstrates Meaningful Improvements in OS, PFS in Patients with Limited-stage SCLC

Patient Perspective: Exercise Prescriptions Needed for Lung Cancer Patients

Glecirasib Shows Promise in Treating Advanced Lung Cancer Harboring KRAS G12C Mutations

US FDA Grants Accelerated Approval to Tarlatamab-dlle for Extensive-stage Small Cell Lung Cancer

CROWN Results Demonstrate Longest Progression-Free Survival in Advanced NSCLC Seen to Date

Subcutaneous Amivantamab Leads to Unexpected OS Improvement vs. IV Dosing in Refractory, EGFR+ Advanced NSCLC

KRYSTAL-12 Supports Previous Evidence Showing Adagrasib is Superior to Docetaxel in Pretreated Advanced KRAS-mutated NSCLC